First drug for fatal organ transplant complications gets FDA’s blessing

(MedPage Today) – The U.S. Food and Drug Administration (FDA) has approved narsoplimab (Yartemlea) as the first treatment for hematopoietic stem cell transplantation (HSCT)-associated thrombotic microangiopathy in adults and children ages 2 years and older, the maker of Omeros said Wednesday.